BIO-TECHNE Corp (OQ:TECH)

Business Focus: Biotechnology & Medical Research

Apr 10, 2024 07:00 am ET
BIO-TECHNE TO HOST CONFERENCE CALL ON MAY 1, 2024, TO ANNOUNCE THIRD QUARTER FISCAL 2024 FINANCIAL RESULTS
MINNEAPOLIS, April 10, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that management will host a conference call and webcast on Wednesday, May 1, 2024, at 8:00 a.m. CDT to review third quarter fiscal 2024 financial results.
Apr 08, 2024 07:00 am ET
BIO-TECHNE SURPASSES 10,000 PEER-REVIEWED PUBLICATIONS CITING RNAscope TECHNOLOGY
Advanced Cell Diagnostics (ACD) achieves significant global customer adoption milestone
Apr 03, 2024 07:00 am ET
BIO-TECHNE TO PRESENT AT THE 2024 AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR) CONFERENCE
MINNEAPOLIS, April 3, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today announced it will showcase its portfolio of solutions to advance cancer research from target discovery to cell therapy development at the upcoming annual meeting of the American Association for Cancer Research (AACR), taking place April 5-10, 2024, in San Diego, California.
Apr 01, 2024 07:00 am ET
BIO-TECHNE RECEIVES CiteAb'S ELISA KIT SUPPLIER OF THE YEAR AND SPATIAL BIOLOGY INNOVATION AWARDS
MINNEAPOLIS, April 1, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH), a leading provider of innovative tools and bioactive reagents for the research and clinical diagnostic communities today announced that its R&D Systems brand has been named "ELISA Kit Supplier of the Year" in CiteAb's prestigious annual industry awards. Additionally, Advanced Cell Diagnostics (ACD), part of Bio-Techne's Spatial Biology Division, was named winner of "The Innovation Award" in recognition of its RNAscope™ ISH technology and its role in helping to advance scientific discovery.
Mar 28, 2024 09:00 am ET
BIO-TECHNE AND NIKON INSTRUMENTS INC. ANNOUNCE PARTNERSHIP TO EXPAND ACCESS TO INNOVATIVE SPATIAL BIOLOGY SERVICES
MINNEAPOLIS, March 28, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) is pleased to announce that Lunaphore, part of Bio-Techne's Spatial Biology Division, is partnering with Nikon Instruments Inc. (Nikon) to expand access to spatial biology services with the COMET™ platform for US-based biotech, pharma, and academic customers.
Mar 22, 2024 07:00 am ET
BIO-TECHNE RECEIVES EUROPEAN IVDR CERTIFICATION FOR DIAGNOSTIC TEST TO MONITOR CHRONIC MYELOID LEUKEMIA
The QuantideX® qPCR BCR-ABL IS Kit is now compliant with the latest diagnostic regulations in Europe
Feb 01, 2024 05:30 am ET
BIO-TECHNE DECLARES DIVIDEND
MINNEAPOLIS, Feb. 1, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) announced that its Board of Directors has decided to pay a dividend of $0.08 per share for the quarter ended December 31, 2023. The quarterly dividend will be payable February 26, 2024, to all common shareholders of record on February 12, 2024. Future cash dividends will be considered by the Board of Directors on a quarterly basis.
Feb 01, 2024 05:30 am ET
BIO-TECHNE RELEASES SECOND QUARTER FISCAL 2024 RESULTS
MINNEAPOLIS, Feb. 1, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today reported its financial results for the second quarter ended December 31, 2023.
Jan 29, 2024 06:00 am ET
BIO-TECHNE'S ADVANCED CELL DIAGNOSTICS (ACD) SETS NEW STANDARD IN SPATIAL BIOLOGY WITH PROTEASE-FREE RNASCOPE MULTIOMICS
Advanced Cell Diagnostics (ACD), a Bio-Techne spatial biology brand, achieves technical breakthrough enabling protease-free, same-slide detection of protein and RNA biomarkers using industry-leading RNAscope™ technology.
Jan 25, 2024 06:00 am ET
LUNAPHORE AND ACD REVOLUTIONIZE SPATIAL BIOLOGY RESEARCH WITH THE LAUNCH OF THE FIRST FULLY AUTOMATED, SAME-SECTION, HYPERPLEX MULTIOMICS APPLICATION
MINNEAPOLIS, Jan. 25, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that its spatial biology brands, Lunaphore and Advanced Cell Diagnostics (ACD), will launch the first fully automated spatial multiomics workflow with same-section hyperplex detection of RNA and protein biomarkers. This state-of-the-art solution revolutionizes the field of predictive biomarker research and drug development. The best-in-class multiomics solution leverages ACD's RNAscope™ HiPlex RNA detection and Lunaphore's universal multiplex sequential immunofluorescence (seqIF™) technology on t
Jan 24, 2024 06:00 am ET
SCIENTISTS AT THE WCBP CONFERENCE HIGHLIGHT ADVANCEMENTS IN PROTEIN BIOTHERAPEUTIC CHARGE HETEROGENEITY CHARACTERIZATION USING THE MauriceFlex™ SYSTEM
MINNEAPOLIS, Jan. 24, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) had the honor of welcoming presentations from leading scientists from two major biopharmaceutical companies, Pfizer and Sanofi, at the WCBP conference held in Washington D.C. The focus of these presentations was on the transformative impact of Bio-Techne's MauriceFlex™ system on their biotherapeutic development processes. MauriceFlex™, known for its automated capillary isoelectric focusing (icIEF), also enables protein charge fractionation, allowing charge variant characterization in downstream analytics like ma
Jan 16, 2024 06:00 am ET
BIO-TECHNE TO HOST CONFERENCE CALL ON FEBRUARY 1, 2024, TO ANNOUNCE SECOND QUARTER FISCAL 2024 FINANCIAL RESULTS
MINNEAPOLIS, Jan. 16, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that management will host a conference call and webcast on Thursday, February 1, 2024, at 8:00 a.m. CST to review second quarter fiscal 2024 financial results.
Jan 05, 2024 06:00 am ET
BIO-TECHNE ANNOUNCES APPOINTMENT OF MATTHEW F. McMANUS AS PRESIDENT, DIAGNOSTICS AND GENOMICS SEGMENT
MINNEAPOLIS, Jan. 5, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced Matthew F. McManus has been appointed President, Diagnostics and Genomics Segment, effective January 8, 2024. Dr. McManus succeeds Kim Kelderman, who will become Bio-Techne's Chief Executive Officer effective February 1, 2024.
Jan 04, 2024 06:00 am ET
BIO-TECHNE TO SHOWCASE CELL AND GENE THERAPY MANUFACTURING TOOLS AT PHACILITATE ADVANCED THERAPIES WEEK 2024
MINNEAPOLIS, Jan. 4, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced it will present its portfolio of products and solutions to enable cell and gene therapy development and manufacturing at Phacilitate's Advanced Therapies Week, taking place January 16-19 at the Miami Beach Convention Center in Miami, Florida.
Dec 21, 2023 06:00 am ET
BIO-TECHNE TO PRESENT AT THE 42nd ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE
MINNEAPOLIS, Dec. 21, 2023 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that Kim Kelderman, current Chief Operating Officer, and Chief Executive Officer effective February 1, 2024, will present at the 42nd Annual J.P. Morgan Healthcare Conference on Wednesday, January 10, 2024, at 9:00 a.m. PST. A live webcast of the presentation can be accessed via the IR Calendar page of Bio-Techne's Investor Relations website at https://investors.bio-techne.com/ir-calendar.
Dec 20, 2023 06:00 am ET
BIO-TECHNE ANNOUNCES SUBMISSION OF FDA DRUG MASTER FILE FOR EXCELLERATE GMP IPSC EXPANSION MEDIUM SUPPORTING STEM CELL THERAPY
MINNEAPOLIS, Dec. 20, 2023 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that it has filed a Drug Master File (DMF) with the U.S. Food and Drug Administration (FDA) for its ExCellerate™ GMP iPSC Expansion Medium, Animal Free (CCM0036-GMP), supporting the development and manufacture of regenerative medicine and stem cell therapies.
Dec 14, 2023 06:00 am ET
LUNAPHORE AND SIB AWARDED INNOSUISSE FUNDING TO DEVELOP INNOVATIVE AI-BASED ASSAY DEVELOPMENT TOOLS
MINNEAPOLIS, Dec. 14, 2023 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that Lunaphore, a Bio-Techne brand, and SIB Swiss Institute of Bioinformatics, have been awarded Innosuisse funding for an innovation project. The collaboration aims to develop novel AI-based assay development tools for spatial biology on Lunaphore's COMET™ to further accelerate the adoption of multiplex sequential immunofluorescence (seqIF™) technology in research.
Nov 27, 2023 06:00 am ET
BIO-TECHNE TO PRESENT AT THE 6TH ANNUAL EVERCORE ISI HEALTHCONx CONFERENCE
MINNEAPOLIS, Nov. 27, 2023 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that Chuck Kummeth, President and Chief Executive Officer, and Kim Kelderman, Chief Operating Officer will present at the 6th Annual Evercore ISI HealthCONx Conference on Wednesday, November 29, 2023, at 2:10 p.m. EST. A live webcast of the presentation can be accessed via the IR Calendar page of Bio-Techne's Investor Relations website at https://investors.bio-techne.com/ir-calendar.
Nov 13, 2023 06:00 am ET
BIO-TECHNE TO PRESENT AT INVESTOR HEALTHCARE CONFERENCES
MINNEAPOLIS, Nov. 13, 2023 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that it will present at the following investor conferences:
Nov 02, 2023 07:00 am ET
ASURAGEN TO PRESENT NOVEL CLINICAL TESTING DATA AT AMP 2023 CONFERENCE
Kitted assays for clinical laboratories streamline the detection of challenging genes and variants to improve results for underrepresented populations
Oct 31, 2023 06:30 am ET
BIO-TECHNE DECLARES DIVIDEND
MINNEAPOLIS, Oct. 31, 2023 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) announced that its Board of Directors has decided to pay a dividend of $0.08 per share for the quarter ended September 30, 2023. The quarterly dividend will be payable November 24, 2023, to all common shareholders of record on November 10, 2023. Future cash dividends will be considered by the Board of Directors on a quarterly basis.
Oct 31, 2023 06:30 am ET
BIO-TECHNE RELEASES FIRST QUARTER FISCAL 2024 RESULTS
MINNEAPOLIS, Oct. 31, 2023 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today reported its financial results for the first quarter ended September 30, 2023.
Oct 25, 2023 09:00 am ET
LEADING RESEARCH INSTITUTES TO PRESENT NEW DATA USING LUNAPHORE'S COMET™ TECHNOLOGY AT THE SOCIETY FOR IMMUNOTHERAPY OF CANCER (SITC) 38th ANNUAL MEETING
MINNEAPOLIS and LAUSANNE, Switzerland, Oct. 25, 2023 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that Lunaphore, a Bio-Techne brand, will have its technologies featured in several presentations by prominent research centers at the Society for Immunotherapy of Cancer's (SITC) 38th Annual Meeting, taking place in San Diego, November 1-5, 2023. The recent studies will demonstrate the unmatched spatial biology capabilities of the company's universal, end-to-end COMET™ product suite, addressing complex biological questions from various research areas. COMET™ is the only
Oct 19, 2023 07:00 am ET
BIO-TECHNE APPOINTS KIM KELDERMAN AS CHIEF EXECUTIVE OFFICER
MINNEAPOLIS, Oct. 19, 2023 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that its Board of Directors appointed Kim Kelderman as President and Chief Executive Officer effective February 1, 2024. Concurrent with his role as CEO, Mr. Kelderman will also become a member of Bio-Techne's Board of Directors. Prior to assuming CEO responsibilities, Mr. Kelderman will become Chief Operating Officer (COO) effective November 1, 2023, where he will be responsible for the day-to-day operations of the Company. Mr. Kelderman succeeds Chuck Kummeth, who will be retiring from the comp
Oct 16, 2023 07:00 am ET
BIO-TECHNE ACHIEVES ISO 13485 CERTIFICATION FOR ITS WALLINGFORD, CT MANUFACTURING FACILITY
MINNEAPOLIS, Oct. 16, 2023 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH), a leading provider of proteins, antibodies and Immunoassays today announced that its Wallingford, CT facility has received ISO 13485:2023 certification for its quality management system (QMS), demonstrating the company's commitment to producing products for clinical applications. The company's Wallingford site manufacturers Bio-Techne's cartridge-based Simple Plex™ immunoassays for its automated Ella™ multiplexing immunoassay platform, a rapid and hands-free precision biomarker detection system.
Oct 10, 2023 07:00 am ET
BIO-TECHNE TO HOST CONFERENCE CALL ON OCTOBER 31, 2023, TO ANNOUNCE FIRST QUARTER FISCAL 2024 FINANCIAL RESULTS
MINNEAPOLIS, Oct. 10, 2023 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that management will host a conference call and webcast on Tuesday, October 31, 2023, at 8:00 a.m. CDT to review first quarter fiscal 2024 financial results.
Sep 28, 2023 06:00 am ET
DR. JORDAN LASER AWARDED AMP MERITORIOUS SERVICE AWARD
MINNEAPOLIS, Sept. 28, 2023 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that Dr. Jordan Laser has received the AMP Meritorious Service Award from the Association for Molecular Pathology (AMP). Dr. Laser is receiving this honor to recognize his dedication and effort behind the scenes to position AMP as the premier molecular diagnostics professional association around the world.
Sep 27, 2023 07:00 am ET
SCIENTISTS AT CE PHARM CONFERENCE DESCRIBE HOW Maurice™ AND MauriceFlex™ SYSTEMS TRANSFORM THEIR PROTEIN ANALYSIS
MINNEAPOLIS, Sept. 27, 2023 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) was pleased to host presentations by three industry experts yesterday at the CASSS CE Pharm conference in Philadelphia, PA. These industry experts highlighted how Bio-Techne's ProteinSimple branded Maurice™ and MauriceFlex™ systems improved their therapeutic development workflows. Both systems offer automated capillary isoelectric focusing (icIEF), which is the gold standard for protein charge analysis, and capillary electrophoresis sodium dodecyl sulfate (CE-SDS) for size analysis. MauriceFlex™ adds protein ch
Sep 26, 2023 07:00 am ET
BIO-TECHNE INTEGRATES ITS MAURICE SYSTEM WITH THE THERMO SCIENTIFIC CHROMELEON CHROMATOGRAPHY DATA SYSTEM
MINNEAPOLIS, Sept. 26, 2023 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) is pleased to launch the new Maurice Chromeleon Driver Kit, which enables control of its Maurice™ instrument with the Thermo Scientific™ Chromeleon™ Chromatography Data System (CDS). In addition to Compass for iCE, and Waters™ Empower® CDS, scientists now can use Chromeleon CDS to analyze protein charge and size data generated from the Maurice system. This exciting development adds to the broad analytical capabilities on the Maurice system to provide a streamlined data analysis and management workflow.
Sep 25, 2023 07:00 am ET
BIO-TECHNE ISSUES 2023 CORPORATE SUSTAINABILITY REPORT
MINNEAPOLIS, Sept. 25, 2023 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today issued its 2023 Corporate Sustainability Report (CSR), detailing the continued progress advancing its Environmental, Social and Governance (ESG) initiatives. Bio-Techne's CSR is organized around four key pillars: Our People, Advancing Science, Governance and Operational Integrity, and The Environment. Bio-Techne's EPIC values (Empowerment, Passion, Innovation and Collaboration) remain the backbone of our corporate culture and provide the foundation for our approach to continuously improving our corporate
Sep 19, 2023 02:00 am ET
Cizzle and Bio-Techne Announce Completion of Evaluation Programme for Detection of CIZ1B Using ProteinSimple Branded Simple Western™ Platform
LONDON and MINNEAPOLIS, Sept. 19, 2023 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) and Cizzle Biotechnology Holdings plc, the UK-based diagnostics developer, are pleased to announce recent progress evaluating specific monoclonal antibodies for Cizzle's CIZ1B cancer biomarker. Cizzle has successfully completed an evaluation programme aimed at assessing the feasibility of using the Simple Western platform from ProteinSimple (a Bio-Techne Brand) for high throughput detection of the CIZ1B cancer biomarker which may be useful in the detection of early-stage lung cancer.
Jul 13, 2023 07:00 am ET
BIO-TECHNE TO HOST CONFERENCE CALL ON AUGUST 8, 2023, TO ANNOUNCE FOURTH QUARTER AND FISCAL 2023 FINANCIAL RESULTS
MINNEAPOLIS, July 13, 2023 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that management will host a conference call and webcast on Tuesday, August 8, 2023, at 8:00 a.m. CDT to review fourth quarter and fiscal 2023 financial results.
Jul 10, 2023 07:00 am ET
BIO-TECHNE COMPLETES LUNAPHORE ACQUISITION
MINNEAPOLIS, July 10, 2023 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today announced it has completed the acquisition of Lunaphore Technologies SA, a leading developer of fully automated spatial biology solutions. Bio-Techne and Lunaphore are combining forces to accelerate their spatial biology leadership position in translational and clinical research markets.
Jun 22, 2023 08:00 am ET
BIO-TECHNE TO ACQUIRE LUNAPHORE
MINNEAPOLIS and TOLOCHENAZ, Switzerland, June 22, 2023 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH), a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities, today announced it has reached an agreement to acquire Lunaphore, Inc. Bio-Techne anticipates the acquisition to close in the first quarter of its fiscal 2024.
Jun 22, 2023 08:00 am ET
Lunaphore to Get Acquired by Bio-Techne
Lunaphore Technologies SA, a Swiss life sciences company developing technology to enable spatial biology in every laboratory, today announced it has reached an agreement to be acquired by
Jun 01, 2023 07:00 am ET
BIO-TECHNE SUCCESSFUL ON CLAIM OF REVERSE ENGINEERING BY MILTENYI BIOTEC
MINNEAPOLIS, June 1, 2023 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that it prevailed on a claim that Miltenyi Biotec B.V. & Co. KG commercialized antibodies it developed based on information obtained by reverse engineering Bio-Techne's proprietary R&D Systems branded TIGIT and CCR-7 antibodies. Specifically, the Court held "it has been proven that [Miltenyi's] TIGIT and CCR-7 antibodies are the result of reverse engineering of [Bio-Techne's] antibodies." In addition to finding that Miltenyi has been marketing and selling these reverse engineered antibodie
May 25, 2023 07:00 am ET
BIO-TECHNE TO PRESENT AT THE 2023 JEFFERIES HEALTHCARE CONFERENCE
MINNEAPOLIS, May 25, 2023 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that Jim Hippel, Executive Vice President and Chief Financial Officer, will present at the 2023 Jefferies Healthcare Conference on Thursday, June 8, 2023, at 12:30 p.m. EDT. A live webcast of the presentation can be accessed via the IR Calendar page of Bio-Techne's Investor Relations website at https://investors.bio-techne.com/ir-calendar.
May 18, 2023 07:00 am ET
EXOSOME DIAGNOSTICS RELEASES INTERIM RESULTS FROM CLINICAL STUDY OF PROSTATE CANCER RISK TEST
Halfway through 5-year study, ExoDx Prostate Test offers more accurate stratification of high- and low-risk patients compared to standard of care
May 16, 2023 07:00 am ET
BIO-TECHNE COMMERCIALIZES RNASCOPE SPATIAL BIOLOGY WORKFLOW FOR THE STANDARD BIOTOOLS HYPERION IMAGING SYSTEM
Enabling Bio-Techne's gold-standard RNAscope ISH technology with Imaging Mass Cytometry detection to accelerate multiomic interrogation of health and disease.
May 12, 2023 09:07 am ET
BIO-TECHNE TO PRESENT AT THE 2023 RBC CAPITAL MARKETS GLOBAL HEALTHCARE CONFERENCE
MINNEAPOLIS, May 12, 2023 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that Jim Hippel, Executive Vice President and Chief Financial Officer, will present at the 2023 RBC Capital Markets Global Healthcare Conference on Tuesday, May 16, 2023, at 2:35 p.m. EDT. A live webcast of the presentation can be accessed via the IR Calendar page of Bio-Techne's Investor Relations website at https://investors.bio-techne.com/ir-calendar.
May 10, 2023 07:00 am ET
BIO-TECHNE ANNOUNCES LAUNCH OF KAPPA AND LAMBDA RNAscope ISH PROBES AS ANALYTE SPECIFIC REAGENTS (ASRs) FOR THE DETECTION OF IMMUNOGLOBULIN KAPPA AND LAMBDA LIGHT CHAINS mRNA
MINNEAPOLIS, May 10, 2023 /PRNewswire/ -- Bio-Techne (NASDAQ: TECH), a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities today announced the launch of two new RNAscope™ in situ Hybridization Probes Kappa and Lambda as analyte specific reagents (ASRs) for the detection of immunoglobulin kappa and lambda light chains mRNA in B-cells.
May 03, 2023 06:30 am ET
BIO-TECHNE DECLARES DIVIDEND
MINNEAPOLIS, May 3, 2023 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) announced that its Board of Directors has decided to pay a dividend of $0.08 per share for the quarter ended March 31, 2023. The quarterly dividend will be  payable May 26, 2023, to all common shareholders of record on May 15, 2023. Future cash dividends will be considered by the Board of Directors on a quarterly basis.
May 03, 2023 06:30 am ET
BIO-TECHNE RELEASES THIRD QUARTER FISCAL 2023 RESULTS
MINNEAPOLIS, May 3, 2023 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today reported its financial results for the third quarter ended March 31, 2023.
May 02, 2023 07:00 am ET
BIO-TECHNE TO PRESENT AT THE BofA SECURITIES 2023 HEALTH CARE CONFERENCE
MINNEAPOLIS, May 2, 2023 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that Chuck Kummeth, President and Chief Executive Officer, will present at the BofA Securities 2023 Health Care Conference on Wednesday, May 10, 2023, at 1:40 p.m. PDT. A live webcast of the presentation can be accessed via the IR Calendar page of Bio-Techne's Investor Relations website at https://investors.bio-techne.com/ir-calendar.
Apr 17, 2023 07:00 am ET
BIO-TECHNE AND LUNAPHORE ESTABLISH STRATEGIC PARTNERSHIP TO DEVELOP THE FIRST FULLY AUTOMATED SAME-SLIDE SPATIAL MULTIOMICS SOLUTION
Bringing together Bio-Techne's gold standard RNAscope™ technology with Lunaphore's multiplex sequential immunofluorescence (seqIF™) COMET™ system to develop a best-in-class end-to-end multiomics workflow.
Apr 13, 2023 07:00 am ET
BIO-TECHNE TO SHOWCASE INNOVATIVE CANCER RESEARCH, CELL THERAPY AND MANUFACTURING TOOLS AT AACR 2023 CONFERENCE
MINNEAPOLIS, April 13, 2023 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced it will present its portfolio of products and solutions to advance cancer research and enable cell and gene therapy development and manufacturing at the upcoming annual meeting of the American Association for Cancer Research (AACR), taking place April 14-19 in Orlando, Florida.  
Apr 12, 2023 07:00 am ET
BIO-TECHNE TO HOST CONFERENCE CALL ON MAY 3, 2023, TO ANNOUNCE THIRD QUARTER 2023 FINANCIAL RESULTS
MINNEAPOLIS, April 12, 2023 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that management will host a conference call and webcast on Wednesday, May 3, 2023, at 8:00 a.m. CDT to review third quarter 2023 financial results.
Apr 05, 2023 07:00 am ET
BIO-TECHNE CELEBRATES MILESTONE WITH MORE THAN 1,000 ELLA™ INSTRUMENTS NOW IN OPERATION
MINNEAPOLIS, April 5, 2023 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced it that it has reached a significant milestone with more than 1,000 Ella™ automated immunoassay instruments now in the field. The achievement is a testament to the growing demand across scientific and clinical research sectors for a fast and efficient immunoassay solution capable of delivering precise, and reliable biomarker analysis. 
Apr 03, 2023 07:00 am ET
BIO-TECHNE COMPLETES INVESTMENT IN WILSON WOLF MANUFACTURING
MINNEAPOLIS, April 3, 2023 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced it has completed its investment in Wilson Wolf Manufacturing. Wilson Wolf achieved the trailing 12-month earnings before interest, taxes, depreciation, and amortization (EBITDA) target of $55 million, triggering Bio-Techne's initial investment in the company. Bio-Techne's $257 million investment gives the Company a 20% ownership stake in Wilson Wolf. The agreement includes the right to acquire the remaining ownership in Wilson Wolf for $1 billion upon its achievement of $226 million in trailing 1
Mar 15, 2023 07:00 am ET
BIO-TECHNE ANNOUNCES COMPLETION OF CELL AND GENE THERAPY CATAPULT PROCESS ANALYTICAL TECHNOLOGY (PAT) CONSORTIUM
MINNEAPOLIS, March 15, 2023 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced it has completed its participation in the Cell and Gene Therapy Catapult Process Analytical Technology (Catapult PAT) consortium, a multi-year collaboration involving 24 partner companies, technology providers, therapy developers, and charities. The Catapult PAT consortium is the first initiative of this scale and functional expertise with member companies and organizations collaborating to develop cell and gene therapy-specific process analytical technologies.   
Feb 24, 2023 07:40 am ET
ExoDx PROSTATE TEST GRANTED EXPANDED COVERAGE BY MEDICARE
Medicare contractor National Government Services finalizes local coverage determination for biomarker testing related to prostate cancer to include repeat biopsies and yearly testing
Feb 14, 2023 06:00 am ET
BIO-TECHNE AND CELL SIGNALING TECHNOLOGY ANNOUNCE PARTNERSHIP TO VALIDATE SIMPLE WESTERN ANTIBODIES
MINNEAPOLIS, Feb. 14, 2023 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) and Cell Signaling Technology (CST) announced today the addition of Simple Western™ validation to CST antibodies. This will allow researchers in various disciplines an easier way to study important molecular signaling pathways on a trusted and validated platform. Obtaining accurate data efficiently and fast is key to advancing drug discovery and development. This ongoing partnership will allow for an expanded menu of Simple Western validated antibodies for various targets across multiple disciplines.
Feb 02, 2023 05:30 am ET
BIO-TECHNE DECLARES DIVIDEND
MINNEAPOLIS, Feb. 2, 2023 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) announced that its Board of Directors has decided to pay a dividend of $0.08 per share for the quarter ended December 31, 2022. The quarterly dividend will be payable February 27, 2023, to all common shareholders of record on February 13, 2023. Future cash dividends will be considered by the Board of Directors on a quarterly basis.
Feb 02, 2023 05:30 am ET
BIO-TECHNE RELEASES SECOND QUARTER FISCAL 2023 RESULTS
MINNEAPOLIS, Feb. 2, 2023 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today reported its financial results for the second quarter ended December 31, 2022.
Jan 31, 2023 06:00 am ET
BIO-TECHNE ANNOUNCES RETIREMENT, APPOINTMENT OF GENERAL COUNSEL
MINNEAPOLIS, Jan. 31, 2023 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced Shane Bohnen has been appointed Senior Vice President, General Counsel effective March 3, 2023.  Mr. Bohnen succeeds Brenda Furlow, who will be retiring from the Company after serving as Executive Vice President and General Counsel for the past nine years. Brenda has been and will continue to provide transition support until her March 3, 2023, retirement and will serve in a consulting capacity for special projects going forward.   
Jan 26, 2023 06:00 am ET
BIO-TECHNE LAUNCHES THE MauriceFlex™ SYSTEM, ADDING cIEF FRACTIONATION CAPABILITY TO THE GOLD STANDARD MAURICE ASSAYS
MINNEAPOLIS, Jan. 26, 2023 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced the launch of its ProteinSimple-branded MauriceFlex™ during the WCBP conference in Washington D.C. MauriceFlex™ enables protein charge variant fractionation plus routine cIEF & CE-SDS assays, making it a unique multi-functional system that further streamlines protein characterization workflows.
Jan 17, 2023 06:00 am ET
BIO-TECHNE TO HOST CONFERENCE CALL ON FEBRUARY 2, 2023, TO ANNOUNCE SECOND QUARTER 2023 FINANCIAL RESULTS
MINNEAPOLIS, Jan. 17, 2023 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that management will host a conference call and webcast on Thursday, February 2, 2023, at 8:00 a.m. CST to review second quarter 2023 financial results.
Jan 10, 2023 06:00 am ET
BIO-TECHNE LAUNCHES RNASCOPE PLUS ASSAY TO ADVANCE GENE THERAPY DEVELOPMENT
An integrated assay using proprietary RNAscope™ and miRNAscope™ technologies to measure the biodistribution and function of novel gene therapies and endogenous regulatory RNAs.
Dec 21, 2022 06:00 am ET
BIO-TECHNE TO PRESENT AT THE 41st ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE
MINNEAPOLIS, Dec. 21, 2022 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that Chuck Kummeth, President and Chief Executive Officer, will present at the 41st Annual J.P. Morgan Healthcare Conference on Wednesday, January 11, 2023, at 8:15 a.m. PST. A live webcast of the presentation can be accessed via the IR Calendar page of Bio-Techne's Investor Relations website at https://investors.bio-techne.com/ir-calendar.
Dec 05, 2022 06:00 am ET
BIO-TECHNE RELEASES MITOBRILLIANT™ FLUORESCENT DYES, PROVIDING A NEXT-GENERATION TOOL FOR IMAGING MITOCHONDRIA IN LIVE AND FIXED CELLS
MINNEAPOLIS, Dec. 5, 2022 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced the introduction of MitoBrilliant™ probes.  These novel probes enable the fluorescent labeling and tracking of mitochondria in live and fixed cells.
Dec 01, 2022 06:00 am ET
Bio-Techne and Oxford Nanopore Technologies partner to bring innovative reproductive health and carrier screening solutions to the market
New collaboration will develop assays that offer a streamlined workflow for analysing even the most challenging genes.
Nov 28, 2022 06:00 am ET
BIO-TECHNE TO PRESENT AT THE FIFTH ANNUAL EVERCORE ISI HealthCONx CONFERENCE
MINNEAPOLIS, Nov. 28, 2022 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that Chuck Kummeth, President and Chief Executive Officer, will present at the Fifth Annual Evercore ISI HealthCONx Conference on Tuesday, November 29, 2022, at 8:50 a.m. EST. A live webcast of the presentation can be accessed via the IR Calendar page of Bio-Techne's Investor Relations website at https://investors.bio-techne.com/ir-calendar.
Nov 17, 2022 06:00 am ET
NAMOCELL HIGHLIGHTED IN NATURE PUBLICATION FOR EFFICIENT SINGLE CELL CLONING OF HUMAN PLURIPOTENT STEM CELLS
MINNEAPOLIS, Nov. 17, 2022 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced the publication of a single-cell cloning workflow study using the Namocell™ Single Cell Dispenser in Nature Protocols: Efficient and safe single-cell cloning of human pluripotent stem cells using the chroman 1, emricasan, polyamines, and trans-ISRIB (CEPT) cocktail. This publication outlines a robust and scalable workflow for cloning human pluripotent stem cells (hPSCs) that maximizes the viability of the cells using the Namocell Single Cell Dispenser. The use of the low-pressure microfluidic Nam
Nov 15, 2022 06:00 am ET
BIO-TECHNE ANNOUNCES OPENING OF NEW IMMUNOASSAY MANUFACTURING FACILITY
MINNEAPOLIS, Nov. 15, 2022 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced the opening of its new 52,000 square foot state-of-the-art product innovation and manufacturing facility. The expansion more than doubles the operational footprint at Bio-Techne's Wallingford, Connecticut site and provides a five-fold increase in Ella™ immunoassay cartridge production capacity. Ella is an automated multiplexing immunoassay system, that enables rapid and hands-free precision biomarker detection.
Nov 10, 2022 06:00 am ET
BIO-TECHNE TO PRESENT AT THE STEPHENS ANNUAL INVESTMENT CONFERENCE
MINNEAPOLIS, Nov. 10, 2022 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that Jim Hippel, Executive Vice President and Chief Financial Officer, will present at the Stephens Annual Investment Conference on Thursday, November 17, 2022, at 10:00 a.m. CST. A live webcast of the presentation can be accessed via the IR Calendar page of Bio-Techne's Investor Relations website at https://investors.bio-techne.com/ir-calendar.
Nov 08, 2022 06:00 am ET
BIO-TECHNE TO PRESENT AT THE STIFEL 2022 HEALTHCARE CONFERENCE
MINNEAPOLIS, Nov. 8, 2022 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that Jim Hippel, Executive Vice President and Chief Financial Officer, will present at the Stifel 2022 Healthcare Conference on Tuesday, November 15, 2022, at 2:25 p.m. EST. A live webcast of the presentation can be accessed via the IR Calendar page of Bio-Techne's Investor Relations website at https://investors.bio-techne.com/ir-calendar.
Nov 03, 2022 07:00 am ET
BIO-TECHNE TO PRESENT AT THE CREDIT SUISSE 31ST ANNUAL HEALTHCARE CONFERENCE
MINNEAPOLIS, Nov. 3, 2022 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that Chuck Kummeth, President and Chief Executive Officer, will present at the Credit Suisse 31st Annual Healthcare Conference on Wednesday, November 9, 2022, at 8:35 a.m. PST. A live webcast of the presentation can be accessed via the IR Calendar page of Bio-Techne's Investor Relations website at https://investors.bio-techne.com/ir-calendar.
Nov 01, 2022 06:30 am ET
BIO-TECHNE DECLARES CASH DIVIDEND AND STOCK DIVIDEND
MINNEAPOLIS, Nov. 1, 2022 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) announced that its Board of Directors has decided to pay a dividend of $0.32 per share for the quarter ended September 30, 2022. The quarterly dividend will be  payable November 28, 2022, to all common shareholders of record on November 14, 2022. Future cash dividends will be considered by the Board of Directors on a quarterly basis.
Nov 01, 2022 06:30 am ET
BIO-TECHNE RELEASES FIRST QUARTER FISCAL 2023 RESULTS
MINNEAPOLIS, Nov. 1, 2022 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today reported its financial results for the first quarter ended September 30, 2022.
Oct 31, 2022 07:00 am ET
Asuragen to Showcase Innovative Diagnostic Lab Solutions at AMP 2022 Conference
Company also launches new Armored DNA™ molecular controls for monkeypox and closely related viruses
Oct 18, 2022 07:00 am ET
New Publication from Exosome Diagnostics Demonstrates Proof-of-Concept for Monitoring Astronaut Health in Space
Study indicates that noninvasive exosome-based liquid biopsy would be feasible for monitoring health and disease in people traveling in space
Oct 12, 2022 07:00 am ET
BIO-TECHNE SETS A NEW STANDARD IN HIGHLY SENSITIVE RNA IMAGING WITH THE INTRODUCTION OF VIVID FLUORESCENT DYES FOR SPATIAL BIOLOGY
Bio-Techne brings together gold-standard spatial biology RNAscope™ ISH technology with exceptionally bright TSA Vivid™ Fluorophores to provide industry leading, highly-sensitive RNA detection for any gene, species, or tissue.
Oct 11, 2022 07:00 am ET
BIO-TECHNE INTRODUCES NEW SIMPLE PLEX AAV VIRAL TITER ASSAYS
Simple Plex AAV assays combine industry leading AAV antibody reagents from PROGEN with convenience and simplicity of the fully automated Ella platform.
Oct 10, 2022 07:00 am ET
BIO-TECHNE TO HOST CONFERENCE CALL ON NOVEMBER 1, 2022, TO ANNOUNCE FIRST QUARTER 2023 FINANCIAL RESULTS
MINNEAPOLIS, Oct. 10, 2022 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that management will host a conference call and webcast on Tuesday, November 1, 2022, at 8:00 a.m. CDT to review first quarter 2023 financial results.
Oct 06, 2022 07:00 am ET
BIO-TECHNE COMMERCIALIZES AUTOMATED MULTI-OMIC RNASCOPE ASSAYS FOR SPATIAL VISUALIZATION OF RNA AND PROTEIN BIOMARKERS IN FFPE TISSUES
Bringing together Bio-Techne's gold-standard spatial biology RNAscope ISH technology with Roche's industry-leading chromogen detection portfolio for the Roche DISCOVER ULTRA Platform
Sep 26, 2022 07:00 am ET
Bio-Techne Files Patent Infringement Lawsuit Against Molecular Instruments
Bio-Techne enforces intellectual property for gold standard RNAscope® ISH technology in spatial biology and clinical applications.
Sep 21, 2022 07:00 am ET
MAURICE FLEX™ icIEF ANALYSIS ADDS FRACTIONATION, ENABLING MASS SPEC PEAK CHARACTERIZATION
MINNEAPOLIS, Sept. 21, 2022 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced data demonstrating icIEF fractionation from their soon to be launched Maurice Flex™ instrument was presented at the 2022 CE Pharm conference.  Data generated using customer and National Institute of Standards and Technology (NIST) samples have been presented at multiple conferences in the last 20 months and the presentation at CE Pharm is a continuation of this work.
Sep 19, 2022 07:00 am ET
BIO-TECHNE ISSUES 2022 CORPORATE SUSTAINABILITY REPORT
MINNEAPOLIS, Sept. 19, 2022 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today issued its 2022 Corporate Sustainability Report (CSR), detailing the continued progress advancing its Environmental, Social and Governance (ESG) initiatives. Bio-Techne's CSR is organized around four key pillars: Our People, Advancing Science, Governance and Operational Integrity, and The Environment. Bio-Techne's EPIC values (Empowerment, Passion, Innovation and Collaboration) remain the backbone of our corporate culture and provide the foundation for our approach to continuously improving our corporate
Sep 08, 2022 07:00 am ET
BIO-TECHNE PRESENTS INITIAL DATA ON SJÖGREN'S SYNDROME MONITORING ASSAY
MINNEAPOLIS, Sept. 8, 2022 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today announced that Exosome Diagnostics, a Bio-Techne brand, will present initial data on their novel non-invasive saliva profiling assay for Sjögren's Syndrome diagnosis and monitoring at the 15th International Symposium on Sjögren's Syndrome in Rome, Italy on Friday Sept 9. Exosome Diagnostics' novel Sjögren's Syndrome diagnostic and monitoring tool leverages extracellular vesicles (EVs) to monitor the RNA transcriptome from a small saliva sample.
Sep 06, 2022 07:00 am ET
BIO-TECHNE TO PRESENT AT THE BAIRD 2022 GLOBAL HEALTHCARE CONFERENCE
MINNEAPOLIS, Sept. 6, 2022 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that Chuck Kummeth, President and Chief Executive Officer, will present at the Baird 2022 Global Healthcare Conference on Wednesday, September 14, 2022, at 12:50 p.m. EST. A live webcast of the presentation can be accessed via the IR Calendar page of Bio-Techne's Investor Relations website at https://investors.bio-techne.com/ir-calendar.
Sep 01, 2022 07:00 am ET
BIO-TECHNE TO SEEK APPROVAL TO IMPLEMENT FOUR-FOR-ONE STOCK SPLIT
MINNEAPOLIS, Sept. 1, 2022 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced its plan to request shareholder approval during its upcoming 2022 Annual Meeting of Shareholders (the "Annual Meeting") for an increase in the total number of authorized shares of common stock through an amendment to the Company's Articles of Incorporation to implement a four-for-one forward stock split in the form of a stock dividend. The proposed amendment to the Company's Articles of Incorporation will be voted on by shareholders during Bio-Techne's Annual Meeting on October 27, 2022. Followin
Aug 30, 2022 07:00 am ET
BIO-TECHNE TO PRESENT AT THE MORGAN STANLEY 20th ANNUAL GLOBAL HEALTHCARE CONFERENCE
MINNEAPOLIS, Aug. 30, 2022 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that Jim Hippel, Executive Vice President and Chief Financial Officer, will present at the Morgan Stanley 20th Annual Global Healthcare Conference on Tuesday, September 13, 2022, at 1:30 p.m. EST. A live webcast of the presentation can be accessed via the IR Calendar page of Bio-Techne's Investor Relations website at https://investors.bio-techne.com/ir-calendar.
Aug 29, 2022 07:00 am ET
BIO-TECHNE TO PRESENT AT THE 2022 WELLS FARGO HEALTHCARE CONFERENCE
MINNEAPOLIS, Aug. 29, 2022 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that Jim Hippel, Executive Vice President and Chief Financial Officer, will present at the 2022 Wells Fargo Healthcare Conference on Wednesday, September 7, 2022, at 9:10 a.m. EST. A live webcast of the presentation can be accessed via the IR Calendar page of Bio-Techne's Investor Relations website at https://investors.bio-techne.com/ir-calendar.
Aug 25, 2022 07:00 am ET
MAURICE icIEF ESTABLISHED AS A GREEN METHOD FOR CHARACTERIZATION OF AAV IDENTITY AND STABILITY
MINNEAPOLIS, Aug. 25, 2022 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) announced the publication of a study in the Green Analytical Chemistry journal, titled Establishment of a Platform Imaged Capillary Isoelectric Focusing (icIEF) Characterization Method for Adeno-Associated Virus (AAV) Capsid Proteins. The study, led by Jiaqi Wu, Ph.D., and Chris Heger, Ph.D., describes an icIEF method on Maurice, the flagship CE (capillary electrophoresis) instrument by ProteinSimple (a Bio-Techne brand) for the development, platform suitability, and environmental friendliness (greenness) in eva
Aug 24, 2022 07:00 am ET
BIO-TECHNE INCLUDED IN THE FORBES BEST-IN-STATE EMPLOYERS 2022 LIST
MINNEAPOLIS, Aug. 24, 2022 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that it has been included in the Forbes list of Best-in-State Employers 2022. This prestigious award is presented by Forbes and Statista Inc., the world-leading statistics portal and industry ranking provider. The awards list can currently be viewed on the Forbes website.
Aug 18, 2022 07:00 am ET
BIO-TECHNE ANNOUNCES RELEASE OF QUANTIST LUMINEX® DATA ANALYSIS SOFTWARE
MINNEAPOLIS, Aug. 18, 2022 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that R&D Systems®, a Bio-Techne brand, has released its new Quantist Luminex® data analysis software. Compatible with all available Luminex xMAP® instruments, Quantist software provides fast, reliable analysis of Luminex multiplex assay data, helping researchers extract valuable insights from complex data.
Aug 04, 2022 06:30 am ET
BIO-TECHNE ANNOUNCES CEO TRANSITION PLAN
MINNEAPOLIS, Aug. 4, 2022 /PRNewswire/ -- Bio-Teche Corporation (NASDAQ: TECH) today announced Chuck Kummeth's planned two-year transition from his position as Bio-Techne's Chief Executive Officer (CEO) effective June 30, 2024. The Company's Board of Directors has begun its search for Mr. Kummeth's replacement, evaluating both internal and external candidates to assume the CEO position upon Kummeth's retirement at the end of its fiscal 2024. It is anticipated that Mr. Kummeth will continue to serve on Bio-Techne's Board of Directors upon his retirement.
Aug 04, 2022 06:30 am ET
BIO-TECHNE DECLARES DIVIDEND
MINNEAPOLIS, Aug. 4, 2022 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) announced that its Board of Directors has decided to pay a dividend of $0.32 per share for the quarter ended June 30, 2022. The quarterly dividend will be  payable August 29, 2022, to all common shareholders of record on August 15, 2022. Future cash dividends will be considered by the Board of Directors on a quarterly basis.
Aug 04, 2022 06:30 am ET
BIO-TECHNE RELEASES FOURTH QUARTER FISCAL 2022 RESULTS
MINNEAPOLIS, Aug. 4, 2022 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today reported its financial results for the fourth quarter ended June 30, 2022.
Jul 28, 2022 07:00 am ET
BIO-TECHNE ANNOUNCES LICENSING AGREEMENT AND PARTNERSHIP WITH UNIVERSITY OF DUNDEE
MINNEAPOLIS and DUNDEE, Scotland, July 28, 2022 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced the signing of an exclusive licensing agreement to commercialize The University of Dundee's BromoTAG® system and fund the recruitment of postdoctoral researchers at the University's Centre for Targeted Protein Degradation (CeTPD). CeTPD researchers will create new chemical tools that will be commercialized by Tocris, a Bio-Techne brand, for use by the biopharmaceutical research community. 
Jul 14, 2022 07:00 am ET
BIO-TECHNE TO HOST CONFERENCE CALL ON AUGUST 4, 2022, TO ANNOUNCE FOURTH QUARTER 2022 FINANCIAL RESULTS
MINNEAPOLIS, July 14, 2022 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that management will host a conference call and webcast on Thursday, August 4, 2022, at 8:00 a.m. CDT to review fourth quarter 2022 financial results.
Jul 12, 2022 07:00 am ET
BIO-TECHNE LAUNCHES NEW TURBO CE-SDS™ CARTRIDGE, ACCELERATING PROTEIN PURITY ANALYSIS THROUGHPUT BY 400%
MINNEAPOLIS, July 12, 2022 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that ProteinSimple, a Bio-Techne brand, has launched the innovative Maurice™ Turbo CE-SDS cartridge. As the name suggests, Turbo enables high speed and high resolution analysis of protein size and purity on Maurice, the flagship capillary electrophoresis (CE) instrument of the iCE family. By providing protein purity results in as few as 5.5 minutes, Turbo meets the demand for fast and high throughput sample analysis during discovery, cell culture and formulation stages of biotherapeutic developme
Jun 22, 2022 07:00 am ET
BIO-TECHNE TO ACQUIRE NAMOCELL
MINNEAPOLIS and MOUNTAIN VIEW, Mo., June 22, 2022 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH), a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities, today announced it has reached an agreement to acquire Namocell, Inc. Bio-Techne anticipates the acquisition to close in the first quarter of its fiscal 2023.
May 26, 2022 07:00 am ET
Bio-Techne Celebrates 40,000 Unique RNAscope™ in situ Hybridization Probes, Targeting Any Gene, Any Tissue, Any Species.
Bio-Techne is extending ACD's leadership in the spatial biology market by passing a milestone of offering 40,000 custom probes in over four hundred species
May 25, 2022 07:00 am ET
GLOBAL STUDY DEMONSTRATES ICE3 AND MAURICE CAPILLARY ISOELECTRIC FOCUSING COMPARABILITY IN THE JOURNAL OF ELECTROPHERESIS
MINNEAPOLIS, May 25, 2022 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced the publication of a global study in the Journal of Electrophoresis: Global Intercompany Assessment of icIEF Platform Comparability for the Characterization of Therapeutic Proteins. This publication reports the findings of a multi-company study focused on the comparability of the iCE3 and Maurice instruments, two gold standard analytical platforms for charge heterogeneity analysis of therapeutic proteins. Bio-Techne pioneered the use of imaged capillary isoelectric focusing (icIEF) in 1999 with th
May 19, 2022 07:00 am ET
BIO-TECHNE TO PRESENT AT THE JEFFERIES HEALTHCARE CONFERENCE
MINNEAPOLIS, May 19, 2022 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that Chuck Kummeth, President and Chief Executive Officer, will present at the Jefferies 2022 Healthcare Conference on Wednesday, June 8, 2022, at 9:30 a.m. EDT. A live webcast of the presentation can be accessed via the IR Calendar page of Bio-Techne's Investor Relations website at https://investors.bio-techne.com/ir-calendar.
May 12, 2022 07:00 am ET
Bio-Techne and Nonagen Bioscience Announce Exclusive Supply Agreement for Nonagen's Oncuria® Bladder Cancer Test
MINNEAPOLIS and LOS ANGELES, May 12, 2022 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) and Nonagen Bioscience  today announced an agreement for R&D Systems, a Bio-Techne brand, to exclusively manufacture Nonagen Bioscience's Oncuria® bladder cancer diagnostic panel using xMAP Luminex® technology.
May 10, 2022 07:00 am ET
BIO-TECHNE TO PRESENT AT ANNUAL AMERICAN UROLOGICAL ASSOCIATION CONFERENCE IN NEW ORLEANS
MINNEAPOLIS, May 10, 2022 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today announced that Exosome Diagnostics, a Bio-Techne brand, will have a major scientific presence at the annual American Urological Association Conference (AUA) taking place May 13-16 in New Orleans, LA. Exosome Diagnostics will have two poster presentations, including a podium presentation, six in-booth scientific presentations, and a live symposium with American icon, National Baseball Hall of Famer, and former Baltimore Orioles player "Iron Man" Cal  Ripken, Jr. with leading urologist, Dr. Ronald Tutrone of M
May 04, 2022 06:30 am ET
BIO-TECHNE DECLARES DIVIDEND
MINNEAPOLIS, May 4, 2022 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) announced that its Board of Directors has decided to pay a dividend of $0.32 per share for the quarter ended March 31, 2022. The quarterly dividend will be payable May 27, 2022, to all common shareholders of record on May 16, 2022. Future cash dividends will be considered by the Board of Directors on a quarterly basis.
May 04, 2022 06:30 am ET
BIO-TECHNE RELEASES THIRD QUARTER FISCAL 2022 RESULTS
MINNEAPOLIS, May 4, 2022 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today reported its financial results for the third quarter ended March 31, 2022.
May 02, 2022 07:00 am ET
BIO-TECHNE TO PRESENT AT THE BofA SECURITIES HEALTHCARE CONFERENCE
MINNEAPOLIS, May 2, 2022 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that Chuck Kummeth, President and Chief Executive Officer, will present at the BofA Securities 2022 Healthcare Conference on Wednesday, May 11, 2022, at 2:40 p.m. PST. A live webcast of the presentation can be accessed via the IR Calendar page of Bio-Techne's Investor Relations website at https://investors.bio-techne.com/ir-calendar.
Apr 26, 2022 07:00 am ET
BIO-TECHNE INCLUDED ON THE FORBES BEST EMPLOYERS FOR DIVERSITY 2022 LIST
MINNEAPOLIS, April 26, 2022 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that it has been included on the Forbes list of Best Employers for Diversity 2022. This prestigious award is presented by Forbes and Statista Inc., the world-leading statistics portal and industry ranking provider. The awards list can currently be viewed on the Forbes website.
Apr 13, 2022 07:00 am ET
BIO-TECHNE TO HOST CONFERENCE CALL ON MAY 4, 2022, TO ANNOUNCE THIRD QUARTER 2022 FINANCIAL RESULTS
MINNEAPOLIS, April 13, 2022 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that management will host a conference call and webcast on Wednesday, May 4, 2022, at 8:00 a.m. CDT to review third quarter fiscal 2022 financial results.
Apr 12, 2022 07:00 am ET
BIO-TECHNE AND CYGNUS TECHNOLOGIES, PART OF MARAVAI LIFESCIENCES, INTRODUCE NEW SIMPLE PLEX HEK 293 HCP 3G IMMUNOASSAY
MINNEAPOLIS, April 12, 2022 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) and Cygnus Technologies, part of Maravai LifeSciences (NASDAQ: MRVI), announced today the launch of the Simple Plex™ HEK 293 HCP 3G assay for automated process impurity testing on the Ella™ immunoassay platform.
Mar 17, 2022 07:00 am ET
BIO-TECHNE TO PRESENT AT THE KEYBANC LIFE SCIENCES & MEDTECH INVESTOR FORUM
MINNEAPOLIS, March 17, 2022 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that Will Geist, President, Protein Sciences Segment, will present at the KeyBanc Life Sciences & MedTech Investor Forum on Wednesday, March 23, 2022, at 11:15 a.m. EDT. A live webcast of the presentation can be accessed via the IR Calendar page of Bio-Techne's Investor Relations website at https://investors.bio-techne.com/ir-calendar.
Mar 09, 2022 06:00 am ET
BIO-TECHNE TO PRESENT AT THE BARCLAYS GLOBAL HEALTHCARE CONFERENCE
MINNEAPOLIS, March 9, 2022 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that Chuck Kummeth, President and Chief Executive Officer, will present at the Barclays Global Healthcare Conference on Wednesday, March 16, 2022, at 8:30 a.m. EST. A live webcast of the presentation can be accessed via the IR Calendar page of Bio-Techne's Investor Relations website at https://investors.bio-techne.com/ir-calendar.
Feb 28, 2022 06:00 am ET
BIO-TECHNE TO PRESENT AT THE COWEN 42ND ANNUAL HEALTH CARE CONFERENCE
MINNEAPOLIS, Feb. 28, 2022 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that Jim Hippel, Executive Vice President and Chief Financial Officer, will present at the Cowen 42nd Annual Health Care Conference on Monday, March 7, 2022, at 11:10 a.m. EST. A live webcast of the presentation can be accessed via the IR Calendar page of Bio-Techne's Investor Relations website at https://investors.bio-techne.com/ir-calendar.
Feb 22, 2022 03:01 pm ET
BIO-TECHNE TO PRESENT AT THE CITI 2022 VIRTUAL HEALTHCARE CONFERENCE
MINNEAPOLIS, Feb. 22, 2022 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that Jim Hippel, Executive Vice President and Chief Financial Officer, will present at the Citi 2022 Virtual Healthcare Conference on Thursday, February 24, 2022, at 10:15 a.m. EST. A live webcast of the presentation can be accessed via the IR Calendar page of Bio-Techne's Investor Relations website at https://investors.bio-techne.com/ir-calendar.
Feb 22, 2022 06:00 am ET
BIO-TECHNE ANNOUNCES EXCLUSIVE DEVELOPMENT AND LICENSE AGREEMENT WITH THERMO FISHER SCIENTIFIC FOR ExoTRU® KIDNEY TRANSPLANT REJECTION ASSAY
MINNEAPOLIS, Feb. 22, 2022 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced an agreement with Thermo Fisher Scientific to exclusively complete development of and commercialize the ExoTRU kidney transplant rejection test developed by Exosome Diagnostics, a Bio-Techne brand.
Feb 14, 2022 06:00 am ET
BIO-TECHNE ANNOUNCES PUBLICATION OF NEW DATA DEMONSTRATING EXODX PROSTATE TEST CORRELATION WITH POST-PROSTATECTOMY PATHOLOGY OUTCOMES
MINNEAPOLIS, Feb. 14, 2022 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today announced an important publication in World Journal of Urology, entitled Pre–diagnosis urine exosomal RNA (ExoDx EPI score) is associated with post–prostatectomy pathology outcome. Principal investigator Dr. Alexander Kretschmer, urologist from Ludwig Maximilian University of Munich, Germany, and colleagues demonstrated utility of the ExoDx™ Prostate test, or EPI, to address limitations related to prostate biopsy sampling error, prostate biopsy bias as well as multifocality of the disease, providing a more
Feb 11, 2022 06:00 am ET
BIO-TECHNE TO PRESENT AT THE 11th ANNUAL SVB LEERINK GLOBAL HEALTHCARE CONFERENCE
MINNEAPOLIS, Feb. 11, 2022 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that Chuck Kummeth, President and Chief Executive Officer, will present at the 11th Annual SVB Leerink Global Healthcare Conference on Thursday, February 17, 2022, at 9:20 a.m. EST. A live webcast of the presentation can be accessed via the IR Calendar page of Bio-Techne's Investor Relations website at https://investors.bio-techne.com/ir-calendar.
Feb 10, 2022 06:00 am ET
BIO-TECHNE AWARDED ON THE FORBES AMERICA'S BEST EMPLOYERS 2022 LIST
MINNEAPOLIS, Feb. 10, 2022 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that it has been awarded on the Forbes list of America's Best Employers 2022. This prestigious award is presented by Forbes and Statista Inc., the world-leading statistics portal and industry ranking provider.  The awards list can currently be viewed on the Forbes website.
Feb 01, 2022 05:30 am ET
BIO-TECHNE DECLARES DIVIDEND AND NEW SHARE REPURCHASE PROGRAM
MINNEAPOLIS, Feb. 1, 2022 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) announced that its Board of Directors has decided to pay a dividend of $0.32 per share for the quarter ended December 31, 2021. The quarterly dividend will be payable February 25, 2022, to all common shareholders of record on February 11, 2022. Future cash dividends will be considered by the Board of Directors on a quarterly basis.
Feb 01, 2022 05:30 am ET
BIO-TECHNE RELEASES SECOND QUARTER FISCAL 2022 RESULTS
MINNEAPOLIS, Feb. 1, 2022 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today reported its financial results for the second quarter ended December 31, 2021.
Jan 18, 2022 06:00 am ET
BIO-TECHNE ANNOUNCES COMMERCIAL RELEASE OF HIGH SENSITIVITY FLUORESCENT DETECTION STELLAR NIR / IR™ MODULES FOR JESS AUTOMATED WESTERN BLOTTING SYSTEM
MINNEAPOLIS, Jan. 18, 2022 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that ProteinSimple, a Bio-Techne brand, released its Stellar NIR / IR™ Detection Modules for Jess.  Stellar fluorescence modules enable detection of low abundance proteins while multiplexing multiple analytes within the same detection lane, setting a new industry standard for western blotting fluorescence detection sensitivity.  Multi-color immunoassays can also be run alongside total protein staining using Stellar detection modules.
Jan 17, 2022 07:00 am ET
BIO-TECHNE TO HOST CONFERENCE CALL ON FEBRUARY 1, 2022 TO ANNOUNCE SECOND QUARTER 2022 FINANCIAL RESULTS
MINNEAPOLIS, Jan. 17, 2022 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that management will host a conference call and webcast on Tuesday, February 1, 2022, at 8:00 a.m. CST to review second quarter fiscal 2022 financial results.
Jan 07, 2022 03:01 pm ET
BIO-TECHNE ANNOUNCES UPDATED PRESENTATION TIME AT THE J.P. MORGAN HEALTHCARE CONFERENCE
MINNEAPOLIS, Jan. 7, 2022 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that Chuck Kummeth, President and Chief Executive Officer, will present at the 40th Annual J.P. Morgan Healthcare Conference on Wednesday, January 12, 2022, at 8:15 a.m. EST. This presentation time has been updated and reflects the latest schedule. A live webcast of the presentation can be accessed via the IR Calendar page of Bio-Techne's Investor Relations website at https://investors.bio-techne.com/ir-calendar.
Jan 05, 2022 07:00 am ET
Akoya Biosciences and Bio-Techne Partner to Deliver Automated Spatial Multiomics Workflow with Industry-Leading Speed and Resolution
Akoya Biosciences, Inc., (NASDAQ: AKYA), The Spatial Biology Company®, and Bio-Techne (NASDAQ: TECH), a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities, today...
Jan 05, 2022 06:00 am ET
Bio-Techne and Akoya Biosciences Partner to Deliver Automated Spatial Multiomics Workflow with Industry-Leading Speed and Resolution
MINNEAPOLIS and MARLBOROUGH, Mass., Jan. 5, 2022 /PRNewswire/ -- Bio-Techne (NASDAQ: TECH), a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities, and Akoya Biosciences, Inc., (NASDAQ: AKYA), The Spatial Biology Company®, today announced a partnership to develop the first single-cell, spatial multiomics workflow for comprehensive, unbiased analysis of tissue samples.
Jan 03, 2022 06:00 am ET
BIO-TECHNE TO PRESENT AT THE J.P. MORGAN HEALTHCARE CONFERENCE
MINNEAPOLIS, Jan. 3, 2022 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that Chuck Kummeth, President and Chief Executive Officer, will present at the 40th Annual J.P. Morgan Healthcare Conference on Wednesday, January 12, 2022, at 4:30 p.m. EST. A live webcast of the presentation can be accessed via the IR Calendar page of Bio-Techne's Investor Relations website at https://investors.bio-techne.com/ir-calendar.
Dec 27, 2021 06:00 am ET
BIO-TECHNE ANNOUNCES APPOINTMENT OF BRENDA EVERSON AS SVP HUMAN RESOURCES
MINNEAPOLIS, Dec. 27, 2021 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced the appointment of Brenda Everson as Senior Vice President, Human Resources effective January 10, 2022. Ms. Everson succeeds Struan Robertson, who will be retiring from the Company. Mr. Robertson will remain with Bio-Techne through February 11, 2022, to ensure a smooth transition.
Dec 21, 2021 06:00 am ET
BIO-TECHNE ANNOUNCES APPOINTMENT OF WILL GEIST AS PRESIDENT, PROTEIN SCIENCES SEGMENT
MINNEAPOLIS, Dec. 21, 2021 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced William A. Geist has been appointed President, Protein Sciences Segment, effective January 3, 2022.  Mr. Geist succeeds N. David Eansor, who will be retiring from the Company. Mr. Eansor will remain with Bio-Techne through the end of February 2022 to ensure a smooth transition.
Dec 14, 2021 06:00 am ET
BIO-TECHNE ANNOUNCES FUTURE WILSON WOLF PURCHASE AGREEMENT
MINNEAPOLIS and ST. PAUL, Minn., Dec. 14, 2021 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH), a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities, today announced it has entered into an option agreement with Wilson Wolf Corporation.   The agreement includes a potential 20% ownership investment in Wilson Wolf upon its achievement of approximately $100 million in revenue or $50 million in earnings before interest, taxes, depreciation, and amortization (EBITDA) as well as the opportunity to fully acquire t
Dec 08, 2021 06:00 am ET
Bio-Techne Announces Publication of Lateral Flow Technology Proof-of-Concept Data
MINNEAPOLIS, Dec. 8, 2021 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced the publication of an important manuscript in the journal Scientific Reports, a Nature Research journal, showing proof-of-concept of its proprietary lateral flow technology. The manuscript is entitled SARS-CoV-2 antigen rapid diagnostic test for resource limited settings. In this manuscript, Bio-Techne scientists demonstrate a method for developing an inexpensive alternate test for diagnosing active COVID-19 infection caused by SARS-CoV-2 with a minimally invasive anterior nares swab sample.
Nov 22, 2021 06:00 am ET
Bio-Techne To Present At Upcoming Investor Conferences
MINNEAPOLIS, Nov. 22, 2021 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that it will present at two upcoming investor conferences.
Nov 09, 2021 06:00 am ET
Bio-Techne To Present At The Stifel 2021 Virtual Healthcare Conference
MINNEAPOLIS, Nov. 9, 2021  /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that Jim Hippel, Executive Vice President and Chief Financial Officer, will present at the Stifel 2021 Virtual Healthcare Conference on Tuesday, November 16, 2021 at 10:00 a.m. EDT. A live webcast of the presentation can be accessed via the IR Calendar page of Bio-Techne's Investor Relations website at https://investors.bio-techne.com/ir-calendar.
Nov 08, 2021 06:00 am ET
Asuragen Launches New Kit to Enable Broader Coverage of Gene Variants Linked to Cystic Fibrosis
MINNEAPOLIS, Nov. 8, 2021 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today announced that Asuragen, Inc., a Bio-Techne brand, has launched a new kit to detect pathogenic variants in the CFTR gene. The AmplideX® PCR/CE CFTR Kit, intended for research use only, provides broader coverage of the diverse U.S. population1,2 than any other commercially available, targeted CFTR testing assay.
Nov 04, 2021 04:01 pm ET
Bio-Techne To Present At The Credit Suisse 30th Annual Healthcare Conference
MINNEAPOLIS, Nov. 4, 2021 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that Jim Hippel, Executive Vice President and Chief Financial Officer, will present virtually at the Credit Suisse 30th Annual Healthcare Conference on Tuesday, November 9, 2021 at 11:20 a.m. EST. A live webcast of the presentation can be accessed via the IR Calendar page of Bio-Techne's Investor Relations website at https://investors.bio-techne.com/ir-calendar.
Nov 03, 2021 07:00 am ET
Bio-Techne Announces Commercial Availability Of GMP-Grade Proteins From Dedicated GMP Facility
MINNEAPOLIS, Nov. 3, 2021 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced the commercial availability of GMP-grade materials manufactured at  its St. Paul, MN GMP (Good Manufacturing Practices) manufacturing facility. The facility is dedicated to supporting large-scale production of GMP-grade proteins, including animal-free cytokines and growth factors, that are essential components of cell culture media for immuno-oncology, regenerative medicine and gene-modified cell therapy workflows. Cell therapies are rapidly growing fields of medicine that introduce living cells i
Nov 02, 2021 04:01 pm ET
Bio-Techne Named in Inc.'s First-Annual Best-Led Companies
MINNEAPOLIS, Nov. 2, 2021 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced inclusion in Inc.'s first annual Best-Led Companies list, an exciting 12-point measure of management excellence across the middle market — a select, data-driven list of the very strongest U.S. firms with revenue of $50 million to $2 billion. This novel program is the first Inc. recognition list to honor both public and private companies.
Nov 02, 2021 06:30 am ET
Bio-Techne Declares Dividend
MINNEAPOLIS, Nov. 2, 2021 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) announced that its Board of Directors has decided to pay a dividend of $0.32 per share for the quarter ended September 30, 2021. The quarterly dividend will be payable November 26, 2021 to all common shareholders of record on November 12, 2021. Future cash dividends will be considered by the Board of Directors on a quarterly basis.
Nov 02, 2021 06:30 am ET
Bio-Techne Releases First Quarter Fiscal 2022 Results
MINNEAPOLIS, Nov. 2, 2021 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today reported its financial results for the first quarter ended September 30, 2021.
Oct 13, 2021 07:00 am ET
Bio-Techne Announces ExoDx Prostate Test Data Publication in the Journal of Prostate Cancer and Prostatic Diseases
MINNEAPOLIS, Oct. 13, 2021 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today announced that Exosome Diagnostics, a Bio-Techne brand, has published important clinical research in the journal Prostate Cancer and Prostatic Diseases, entitled Predicting high-grade prostate cancer at initial biopsy: clinical performance of the ExoDx (EPI) Prostate Intelliscore test in three independent prospective studies. In this pooled analysis from three independent prospective-validation studies and more than 1200 subjects, principal investigator Dr. Erik Margolis, Chief of Urology at Englewood Hospi
Oct 11, 2021 07:00 am ET
Bio-Techne To Host Conference Call On November 2, 2021 To Announce First Quarter 2022 Financial Results
MINNEAPOLIS, Oct. 11, 2021 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that management will host a conference call and webcast on Tuesday, November 2, 2021, at 8:00 a.m. CDT to review first quarter 2022 financial results.
Sep 14, 2021 07:00 am ET
Bio-Techne Launches ExCellerate™ iPSC Expansion Medium
MINNEAPOLIS, Sept. 14, 2021 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) Bio-Techne announced the launch of a new medium for the expansion and maintenance of induced pluripotent stem cells (iPSCs) for use in both research and translational workflows. The ExCellerate™ iPSC Expansion Medium is the latest addition to Bio-Techne's comprehensive portfolio of products and services for Regenerative Medicine. It is designed to fit seamlessly into their offerings for stem cell workflows, including cell isolation, reprogramming, genome engineering, cell expansion, differentiation and characte
Sep 08, 2021 07:00 am ET
Bio-Techne And Carterra Initiate A Clinical Research Collaboration For COVID-19 Variant Analysis
MINNEAPOLIS and SALT LAKE CITY, Sept. 8, 2021 /PRNewswire/ -- Bio-Techne, a leading supplier of high-quality and innovative tools for life science research, therapeutic manufacturing and clinical diagnostics and Carterra Inc., the world leader in high-throughput antibody screening and characterization, today announced a clinical research collaboration studying COVID-19 variants. New variants, such as Delta, can be more easily transmitted and more likely to evade the immune response of vaccinated or previously infected people. To assess immune responses to new variants and to plan for int
Sep 02, 2021 07:00 am ET
Bio-Techne To Present At The 2021 Virtual Wells Fargo Healthcare Conference
MINNEAPOLIS, Sept. 2, 2021 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that Chuck Kummeth, President and Chief Executive Officer, will present at the 2021 Virtual Wells Fargo Healthcare Conference on Thursday, September 9, 2021 at 2:00 p.m. EDT. A live webcast of the presentation can be accessed via the IR Calendar page of Bio-Techne's Investor Relations website at https://investors.bio-techne.com/ir-calendar.
Aug 24, 2021 06:03 pm ET
Bio-Techne Set to Join S&P 500; Saia, Mimecast & Option Care Health to Join S&P MidCap 400; Others to Join S&P SmallCap 600
NEW YORK, Aug. 24, 2021 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P 500, S&P MidCap 400, and S&P SmallCap 600 effective prior to the opening of trading on Monday, August 30:
Aug 05, 2021 06:30 am ET
Bio-Techne Declares Dividend
MINNEAPOLIS, Aug. 5, 2021 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) announced that its Board of Directors has decided to pay a dividend of $0.32 per share for the quarter ended June 30, 2021. The quarterly dividend will be payable August 27, 2021 to all common shareholders of record on August 16, 2021. Future cash dividends will be considered by the Board of Directors on a quarterly basis.
Aug 05, 2021 06:30 am ET
Bio-Techne Releases Fourth Quarter Fiscal 2021 Results
MINNEAPOLIS, Aug. 5, 2021 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today reported its financial results for the fourth quarter ended June 30, 2021.
Aug 04, 2021 07:00 am ET
Bio-Techne's RNAscope™ Technology Aids in the Retrospective Tissue Diagnosis of COVID-19 in cases with no previous testing for SARS-CoV-2
MINNEAPOLIS, Aug. 4, 2021 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that scientists at the U.S. Centers for Disease Control and Prevention (CDC) recently highlighted the importance of fixed tissue analysis for retrospective diagnosis of SARS-CoV-2 infection and characterization of viral strains, particularly for fatal cases in which no previous testing for SARS-CoV-2 was performed.
Aug 03, 2021 07:00 am ET
Bio-Techne Announces 2021 Investor Day and Webcast
MINNEAPOLIS, Aug. 3, 2021 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that management will host its 2021 Investor Day on Friday, September 10, 2021, starting at 9:00 a.m. EDT. The meeting will take place at the Lotte New York Palace Hotel, 455 Madison Avenue, New York City.
Jul 28, 2021 07:00 am ET
Bio-Techne and PROGEN Introduce New Simple Plex AAV2 Immunoassay
MINNEAPOLIS, July 28, 2021 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) and PROGEN today announced the launch of the Simple Plex™ Adeno-Associated Virus (AAV2) viral titer assay for AAV2 total capsid quantification.  Bio-Techne, owner of the leading ProteinSimple branded protein analysis portfolio of products, and PROGEN will offer the Simple Plex AAV2 viral titer assay on Ella™ instruments, its multiplexing immunoassay system.  Combining the efficiency and reproducibility of the established AAV2 ELISAs from PROGEN with the convenient workflow and robustness of the Ella platform, th
Jul 27, 2021 07:00 am ET
Bio-Techne Announces Commercial Release of RNAscope™ HiPlex V2 Assay for Single Cell Validation and Spatial Transcriptomic Profiling of Complex Tissues on FFPE, Fixed and Fresh Frozen Samples.
MINNEAPOLIS, July 27, 2021 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced the expansion of the Advanced Cell Diagnostics (ACD), a Bio-Techne brand, RNAscope in situ hybridization technology portfolio with the release of new RNAscope HiPlex V2 assay for formalin-fixed paraffin-embedded (FFPE) and fixed and fresh frozen samples for up to 12 targets. RNAscope is a proven and well characterized technology, with over 4400 peer reviewed publications.  The addition of HiPlex V2 advances the field of spatial genomics and ACD's positioning in this rapidly growing field.
Jul 13, 2021 07:00 am ET
Bio-Techne To Host Conference Call On August 5, 2021 To Announce Fourth Quarter 2021 Financial Results
MINNEAPOLIS, July 13, 2021 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that management will host a conference call and webcast on Thursday, August 5, 2021, at 8:00 a.m. CDT to review fourth quarter 2021 financial results.
Jun 28, 2021 07:00 am ET
Bio-techne Announces Opening Of New Ireland Facility
MINNEAPOLIS, June 28, 2021 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today announced the opening of its new Ireland facility located in Dublin. This new facility reflects Bio-Techne's commitment to supporting the broader life sciences industry in Europe as well as expectations for continued growth and staffing needs in this geography.
Jun 24, 2021 07:00 am ET
Bio-Techne and Catamaran Bio Announce Expanded Collaboration for CAR-NK Cell Manufacturing Technologies
MINNEAPOLIS and CAMBRIDGE, Mass., June 24, 2021 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) and Catamaran Bio today announced an expansion of their collaboration for the development of cell engineering and cell process technologies for use by Catamaran in the manufacturing of CAR-NK cell therapy products.  
Jun 15, 2021 07:00 am ET
Renalytix Reports Financial Results for Third Quarter of Fiscal Year 2021
Renalytix AI plc (LSE: RENX) (NASDAQ: RNLX) (“Renalytix” or the “Company”) today reported financial results for the quarter and nine months ended March 31, 2021. Recent Highlights Partnership announced with University of Utah health system to...
Jun 10, 2021 07:00 am ET
Bio-Techne Further Enhances Its Gene Engineering & Cell & Gene Therapy Manufacturing Capabilities
MINNEAPOLIS and LONDON, June 10, 2021 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH), a leader in developing innovative tools and technologies for cell and gene therapy research and manufacturing, has partnered with Autolomous to implement a first of its kind electronic batch record system, AutoloMATETM, at Bio-Techne's GMP cellular manufacturing center. 
Jun 08, 2021 07:00 am ET
Bio-Techne Joins Cell and Gene Therapy Catapult Process Analytical Technology Consortium
MINNEAPOLIS, June 8, 2021 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced it is joining the Cell and Gene Therapy Catapult process analytical technology (PAT) consortium, which includes over 20 pharmaceutical companies, technology providers, therapy developers, and charities.  The consortium will assess the application and combination of multiple technologies for process analytics within the cell and gene therapy industry.
May 04, 2021 07:00 am ET
908 Devices and Bio-Techne Announce Joint Collaboration
908 Devices (NASDAQ: MASS) and Bio-Techne Corporation (NASDAQ: TECH) today announced a joint collabor
Feb 25, 2021 06:00 am ET
Bio-Techne Announces ISO 14001:2015 Certification for the EMEA region of Bio-Techne.
MINNEAPOLIS, Feb. 25, 2021 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH), a leading provider of proteins, antibodies and cytokines today announced that its sites in Abingdon, Langley, Rennes and Wiesbaden received ISO 14001:2015 certification for Environmental Management Systems. These Bio-Techne facilities provide Sales, Marketing, Purchasing, Order Processing, Warehousing, Distribution and Customer Services for the EMEA region.
Feb 23, 2021 06:00 am ET
Bio-Techne and Luminary Therapeutics sign license agreement for use of Bio-Techne's TcBuster™ for the development of Luminary's CAR-T cell therapies
MINNEAPOLIS, Feb. 23, 2021 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced the signing of a license agreement with Luminary Therapeutics for the use of TcBuster™ for the manufacturing of gene-modified cell therapies. TcBuster is Bio-Techne's proprietary non-viral transposon-based gene delivery system used to advance cell therapy manufacturing.  
Feb 16, 2021 06:00 am ET
Bio-Techne To Present At Citi's 2021 Healthcare Services, Medtech, Tools & HCIT Virtual Conference
MINNEAPOLIS, Feb. 16, 2021 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that Chuck Kummeth, President and Chief Executive Officer, will present at Citi's 2021 Healthcare Services, Medtech, Tools & HCIT Virtual Conference on Thursday, February 25, 2021 at 9:50 a.m. EST. A live webcast of the presentation can be accessed via the IR Calendar page of Bio-Techne's Investor Relations website at https://investors.bio-techne.com/ir-calendar.
Feb 11, 2021 06:00 am ET
Bio-Techne Announces Paper Publication In Annals Of Oncology
MINNEAPOLIS, Feb. 11, 2021 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today announced that Exosome Diagnostics, a Bio-Techne brand, has recently published a paper entitled Exosome-based Liquid Biopsies in Cancer: Opportunities and Challenges (Yu, W et al.), in the highly rated peer-reviewed journal, Annals of Oncology (link). This review paper provides unique insight into liquid biopsies and the field of exosomes in the context of other liquid biopsies such as cfDNA and CTC analysis. The exosome field has gone through a rapid growth phase in parallel with the increasing attention o
Feb 10, 2021 10:31 am ET
FDA Adds Kantaro's Semi-Quantitative COVID-19 Antibody Test to Revised Emergency Use Authorization for Convalescent Plasma
NEW YORK, Feb. 10, 2021 /PRNewswire/ -- Kantaro Biosciences, LLC, a joint venture between the Mount Sinai Health System and RenalytixAI (LSE:RENX / NASDAQ: RNLX), and manufacturing partner Bio-Techne Corporation (NASDAQ: TECH), announced that the U.S. Food and Drug Administration (FDA) has added COVID-SeroKlir to the Emergency Use Authorization (EUA) for the use of convalescent plasma for treating COVID-19 in hospitalized patients. COVID-SeroKlir detects the presence and precise level of SARS-CoV-2 IgG antibodies with 98.8% sensitivity and 99.6% specificity.
Feb 10, 2021 06:00 am ET
Bio-Techne To Present At The 2021 SVB Leerink Global Healthcare Conference
MINNEAPOLIS, Feb. 10, 2021 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that Chuck Kummeth, President and Chief Executive Officer, will present at the 2021 SVB Leerink Global Healthcare Conference on Wednesday, February 24, 2021 at 11:20 a.m. EST. A live webcast of the presentation can be accessed via the IR Calendar page of Bio-Techne's Investor Relations website at https://investors.bio-techne.com/ir-calendar.
Feb 08, 2021 06:30 am ET
Kantaro and Atrys Health Partnership Expand Global Footprint of Quantitative COVID-19 Antibody Tests in Europe and South America
NEW YORK, Feb. 8, 2021 /PRNewswire/ -- Kantaro Biosciences, LLC, a joint venture between the Mount Sinai Health System and RenalytixAI (LSE:RENX / NASDAQ: RNLX), and manufacturing partner Bio-Techne Corporation (NASDAQ: TECH), entered into a marketing and distribution agreement with Atrys Health (BME: ATRY), a biomedical company dedicated to providing diagnostic services and medical treatments of excellence. Atrys Health will offer COVID-SeroKlir and COVID-SeroIndex, Kantaro's quantitative SARS-CoV-2 IgG antibody test kits, in select European and South American territories, including Spain,
Feb 03, 2021 06:00 am ET
Bio-Techne Announces Expanded Simple Plex Immunoassay Cartridge Portfolio
MINNEAPOLIS, Feb. 3, 2021 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that ProteinSimple, a Bio-Techne brand, has expanded its Simple PlexTM immunoassay cartridge portfolio to include nine new cartridge formats. These new cartridge offerings provide Simple Plex users with increased flexibility in the number of samples and biomarker assays run on each cartridge. Simple Plex assay cartridges, run on the EllaTM platform, utilizing state-of-the-art microfluidics to deliver a fully automated immunoassay solution. Researchers can customize cartridge lots from a menu of ov
Feb 02, 2021 05:30 am ET
Bio-Techne Declares Dividend
MINNEAPOLIS, Feb. 2, 2021 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) announced that its Board of Directors has decided to pay a dividend of $0.32 per share for the quarter ended December 31, 2020. The quarterly dividend will be payable February 26, 2021 to all common shareholders of record on February 12, 2021. Future cash dividends will be considered by the Board of Directors on a quarterly basis.
Feb 02, 2021 05:30 am ET
Bio-Techne Releases Second Quarter Fiscal 2021 Results
MINNEAPOLIS, Feb. 2, 2021 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today reported its financial results for the second quarter ended December 31, 2020.
Jan 28, 2021 06:00 am ET
Bio-Techne Announces Strategic Investment In Eminence
MINNEAPOLIS, Jan. 28, 2021 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH), a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities, today announced an initial minority strategic equity investment in Changzhou Eminence Biotechnology Co., Ltd. ("Eminence").  Eminence will use the financing proceeds to expand its manufacturing capacity and increase the service capabilities of its China-headquartered GMP media production facility.  Eminence will benefit from Bio-Techne's industry-wide recognition as a high-qualit
Jan 14, 2021 06:00 am ET
Bio-Techne To Host Conference Call On February 2, 2021 To Announce Second Quarter 2021 Financial Results
MINNEAPOLIS, Jan. 14, 2021 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that management will host a conference call and webcast on Tuesday, February 2, 2021, at 8:00 a.m. CST to review second quarter 2021 financial results.
Dec 21, 2020 06:00 am ET
Bio-Techne To Present At The 39th Annual J.P. Morgan Healthcare Conference
MINNEAPOLIS, Dec. 21, 2020 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that Chuck Kummeth, President and Chief Executive Officer, will present at the 39th Annual J.P. Morgan Healthcare Conference on Wednesday, January 13, 2021 at 2:00 p.m. EST. A live webcast of the presentation can be accessed via the IR Calendar page of Bio-Techne's Investor Relations website at https://investors.bio-techne.com/ir-calendar.
Dec 02, 2020 06:00 am ET
Regulus Therapeutics Collaborates With Bio-Techne For Biomarker Development
MINNEAPOLIS, Dec. 2, 2020 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) and Regulus Therapeutics (NASDAQ: RGLS) announced a collaboration to support Regulus with biomarker analysis for the clinical development of RGLS4326, an Autosomal Dominant Polycystic Kidney Disease (ADPKD) treatment.
Nov 25, 2020 06:30 am ET
Kantaro Receives FDA Emergency Use Authorization for Semi-Quantitative COVID-19 Antibody Test Kit that Detects the Presence and Level of SARS-CoV-2 IgG Antibodies
NEW YORK, Nov. 25, 2020 /PRNewswire/ -- Kantaro Biosciences, LLC, a joint venture between the Mount Sinai Health System and RenalytixAI (NASDAQ: RNLX), has received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) for COVID-SeroKlir, its semi-quantitative SARS-CoV-2 IgG antibody test kit. Unlike other antibody tests, COVID-SeroKlir determines the presence and precise level of IgG antibodies and has a broad range of applications in the fight against COVID-19. Through a commercial partnership with Bio-Techne Corporation (NASDAQ: TECH) the test kits are being m
Nov 11, 2020 06:00 am ET
Bio-Techne To Present At The Stephens Annual Investment Conference 2020
MINNEAPOLIS, Nov. 11, 2020 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that Chuck Kummeth, President and Chief Executive Officer, will present at the Stephens Annual Investment Conference 2020 on Tuesday, November 17, 2020 at 3:00 p.m. EST. A live webcast of the presentation can be accessed via the IR Calendar page of Bio-Techne's Investor Relations website at https://investors.bio-techne.com/ir-calendar.
Nov 05, 2020 05:30 am ET
Bio-Techne Declares Dividend
MINNEAPOLIS, Nov. 5, 2020 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) announced that its Board of Directors has decided to pay a dividend of $0.32 per share for the quarter ended September 30, 2020. The quarterly dividend will be payable November 27, 2020 to all common shareholders of record on November 16, 2020. Future cash dividends will be considered by the Board of Directors on a quarterly basis.
Nov 05, 2020 05:30 am ET
Bio-Techne Releases First Quarter Fiscal 2021 Results
MINNEAPOLIS, Nov. 5, 2020 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today reported its financial results for the first quarter ended September 30, 2020.
Nov 04, 2020 06:00 am ET
Bio-Techne To Present At The Stifel 2020 Virtual Healthcare Conference
MINNEAPOLIS, Nov. 4, 2020 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that Chuck Kummeth, President and Chief Executive Officer, will present at the Stifel 2020 Virtual Healthcare Conference on Monday, November 16, 2020 at 1:20 p.m. EST. A live webcast of the presentation can be accessed via the IR Calendar page of Bio-Techne's Investor Relations website at https://investors.bio-techne.com/ir-calendar.
Nov 02, 2020 06:00 am ET
Bio-Techne To Present At The 29th Annual Credit Suisse Virtual Healthcare Conference
MINNEAPOLIS, Nov. 2, 2020 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today announced that Jim Hippel, Chief Financial Officer, will present at the 29th Annual Credit Suisse Virtual Healthcare Conference on Wednesday, November 11, 2020 at 4:15 p.m. EST. A live webcast of the presentation can be accessed via the IR Calendar page of Bio-Techne's Investor Relations website at https://investors.bio-techne.com/ir-calendar.
Oct 28, 2020 07:30 am ET
EKF and Kantaro Partner to Market Quantitative COVID-19 Antibody Testing in the UK and Europe
NEW YORK, Oct. 28, 2020 /PRNewswire/ -- Kantaro Biosciences, LLC  ("Kantaro"), a joint venture between the Mount Sinai Health System and RenalytixAI plc (LSE: RENX / NASDAQ: RNLX), and manufacturing partner Bio-Techne Corporation (NASDAQ: TECH), entered into a two-year marketing and distribution agreement with EKF Diagnostics, a global leader in diagnostic testing. EKF will offer COVID-SeroKlir, Kantaro's quantitative SARS-CoV-2 IgG antibody test kit, in Europe with exclusive rights in the UK and Germany and COVID-SeroIndex, for the European research market, on a non-exclusive basis. Kantaro
Oct 26, 2020 07:30 am ET
CE Mark Approval Granted to Kantaro COVID-SeroKlir and COVID-SeroIndex Quantitative Antibody Test Kits
NEW YORK, Oct. 26, 2020 /PRNewswire/ -- Kantaro Biosciences, LLC (Kantaro), a joint venture between the Mount Sinai Health System and RenalytixAI (LSE:RENX / NASDAQ: RNLX), and partner Bio-Techne Corporation (NASDAQ: TECH) have received CE marking for COVID-SeroKlir and COVID-SeroIndex, Kantaro's quantitative SARS-CoV-2 IgG antibody test kits. Both kits are available immediately and can be used by any authorized clinical testing laboratory in the European Union without the need for proprietary equipment. Approved as in vitro diagnostics (IVD), COVID-SeroKlir is configured to be most useful i
Oct 19, 2020 07:00 am ET
Bio-Techne Announces Commercial Release Of New SARS-CoV-2 Multi-Antigen Serology Assay Kit For Simple Western
MINNEAPOLIS, Oct. 19, 2020 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that ProteinSimple, a Bio-Techne brand, released its SARS-CoV-2 Multi-Antigen Serology Module for Jess and Wes Simple Western automated western blotting systems.  The SARS-CoV-2 multi-antigen assay for Simple Western offers quantitative characterization of patient serum or plasma derived human IgG antibodies reactive against recombinant Nucleocapsid protein (N), S1 receptor binding domain protein (RBD), S1 subunit full length, S2 subunit full length, and Spike (S1+S2) viral antigens within one 3-
Oct 15, 2020 07:00 am ET
Bio-Techne Announces ISO 13485:2016 Certification for the Woburn, MA Manufacturing Facility
MINNEAPOLIS, Oct. 15, 2020 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH), a leading provider of proteins, antibodies and cytokines today announced that its Woburn, Massachusetts site received ISO 13485:2016 certification for Medical Device and Quality Management Systems. Bio-Techne's Woburn facility produces Cloudz™ Cell Activation Kits, a magnetic-free bead-based technology for the robust and reliable expansion of immune cells, including T cells and NK cells, representing a pivotal component of the cell and gene therapy workflow. This certification is widely recognized international
Oct 13, 2020 07:00 am ET
Bio-Techne To Host Conference Call On November 5, 2020 To Announce First Quarter 2021 Financial Results
MINNEAPOLIS, Oct. 13, 2020 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that management will host a conference call and webcast on Thursday, November 5, 2020, at 8:00 a.m. CST to review first quarter 2021 financial results.
Aug 06, 2020 06:00 am ET
Bio-Techne And NanoString Announce Offering Of RNAscope Reagents Validated For Use With The GeoMx Digital Spatial Profiler
MINNEAPOLIS and SEATTLE, Aug. 6, 2020 /PRNewswire/ -- Bio-Techne (NASDAQ:TECH), a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic markets and NanoString Technologies, Inc. (NASDAQ:NSTG), a leading provider of life science tools for discovery and translational research, today announced an expansion of their partnership to include compatibility with ACD's 21,000+ RNAscope probes and 10 qualified RNAscope probe combinations with GeoMx® Digital Spatial Profiler (DSP) and the recently launched GeoMx Cancer Transcriptome Atlas
Aug 06, 2020 06:00 am ET
NanoString and Bio-Techne Announce Offering of RNAscope Reagents Validated for Use With the GeoMx Digital Spatial Profiler
NanoString Technologies, Inc. (NASDAQ:NSTG), a leading provider of life science tools for discovery and translational research, and Bio-Techne (NASDAQ:TECH), a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic markets, today announced an expansion of their partnership to include compatibility with ACD’s 21,000+ RNAscope probes and 10 qualified RNAscope probe combinations with the GeoMx® Digital Spatial Profiler (DSP) and the recently launched GeoMx Cancer Transcriptome Atlas (CTA).
Aug 04, 2020 06:30 am ET
Bio-Techne Declares Dividend
MINNEAPOLIS, Aug. 4, 2020 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) announced that its Board of Directors has decided to pay a dividend of $0.32 per share for the quarter ended June 30, 2020. The quarterly dividend will be payable August 28, 2020 to all common shareholders of record on August 18, 2020. Future cash dividends will be considered by the Board of Directors on a quarterly basis.
Aug 04, 2020 06:30 am ET
Bio-Techne Releases Fourth Quarter Fiscal 2020 Results
MINNEAPOLIS, Aug. 4, 2020 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today reported its financial results for the fourth quarter ended June 30, 2020.
Aug 03, 2020 07:00 am ET
Bio-Techne And Kantaro Biosciences To Launch A Quantitative Research Use Only COVID-19 Serology Test
MINNEAPOLIS and NEW YORK, Aug. 3, 2020 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) and the Mount Sinai Health System in New York, through its commercial affiliate Kantaro Biosciences LLC (Kantaro), today announced the anticipated launch of the COVID-SeroIndex, a Kantaro Quantitative SARS-CoV-2 IgG Antibody RUO kit. Bio-Techne and Kantaro will leverage a joint commercialization and distribution team to support rapid distribution of the assay to the vaccine development community.  The COVID-SeroIndex test kit is expected to be available for research use in early August.  
Aug 03, 2020 07:00 am ET
Bio-Techne Announces Appointment Of Julie L. Bushman To Its Board Of Directors
MINNEAPOLIS, Aug. 3, 2020 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today announced the appointment of Julie L. Bushman to serve as an independent director on the company's board of directors, effective as of July 31, 2020.  Following the appointment, the board of Bio-Techne will be comprised of ten directors, nine of whom are independent.
Jul 21, 2020 07:00 am ET
Bio-Techne Announces Launch Of ExoCovid-19 Test For Detection Of SARS-CoV-2 In Patient Samples
MINNEAPOLIS, July 21, 2020 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today announced that Exosome Diagnostics, a Bio-Techne brand, has completed validation testing for COVID-19 caused by the novel coronavirus (SARS-CoV-2) and now offers the ExoCovid-19 test for detection of the virus in patient samples. The ExoCovid-19 test will be performed in its CLIA-certified, CAP-accredited laboratory.
Jul 20, 2020 07:00 am ET
Bio-Techne Announces Commercial Release Of New Assay For Detecting ASOs, miRNAs, And siRNAs In Tissue
MINNEAPOLIS, July 20, 2020 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today announced the expansion of the RNAscope™ platform with the release of the miRNAscope™ Assay. The RNAscope technology is an advanced in situ hybridization assay for the spatial visualization of single-molecule RNA with single-cell resolution directly in intact tissues.
Jul 13, 2020 07:00 am ET
Bio-Techne To Host Conference Call On August 4, 2020 To Announce Fourth Quarter 2020 Financial Results
MINNEAPOLIS, July 13, 2020  Bio-Techne Corporation (NASDAQ: TECH) today announced that management will host a conference call and webcast on Tuesday, August 4, 2020, at 8:00 a.m. CDT to review fourth quarter 2020 financial results.
Jun 11, 2020 07:00 am ET
Bio-Techne And ZERO - The End Of Prostate Cancer Announce Partnership To Fund Education And Awareness Campaigns To Empower Men With Prostate Cancer
MINNEAPOLIS, June 11, 2020 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today announced that Exosome Diagnostics, a Bio-Techne brand, has established a new partnership with ZERO – The End of Prostate Cancer, the leading national nonprofit organization in the fight against prostate cancer. ZERO advances research, improves the lives of men and families, and inspires action for patients, physicians, and advocates involved in the prostate cancer cause. ZERO offers comprehensive support for millions of men with prostate cancer, including raising awareness and education for cutting edge te
Jun 09, 2020 07:00 am ET
Bio-Techne Continues to Expand Its Portfolio to Support SARS-CoV-2 and COVID-19 Research and Therapeutic Development
MINNEAPOLIS, June 9, 2020 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) is at the forefront of coronavirus disease 2019 (COVID-19) and SARS-CoV-2 research. This is evidenced by the large number of published research papers on the subject that have cited Bio-Techne products, including the breakthrough Cell paper by Hoffmann et al., which used the R&D Systems™-branded Anti-Human ACE-2 Antibody to demonstrate that SARS-CoV-2 uses ACE-2 as a cell entry receptor. Additionally, the ProteinSimple™-branded Ella™, an automated immunoassay platform, and its COVID-19 Cytokine Storm Panel are
Jun 08, 2020 07:00 am ET
Bio-Techne Announces Release of GMP ProDots Proteins to Support Cell and Gene Therapy Manufacturing Workflows
MINNEAPOLIS, June 8, 2020 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today announced the release of GMP ProDots™ Proteins to support cell and gene therapy manufacturing workflows. GMP ProDots™ Proteins address a critical need to precisely dose and safely add essential proteins such as growth factors and cytokines to therapeutic cell cultures. GMP ProDots Proteins, produced under GMP-grade conditions to meet strict requirements for human therapies, are neatly packaged lyophilized spherical 'dots' of protein contained within a sterile bag designed to be connected to a closed bio-proc
May 27, 2020 07:00 am ET
Bio-Techne To Present At The Jefferies Virtual Healthcare Conference
MINNEAPOLIS, May 27, 2020 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today announced that Chuck Kummeth, President and Chief Executive Officer, will present at the virtual Jefferies Virtual Healthcare Conference on Tuesday, June 2, 2020 at 10:30 a.m. EDT. A live webcast of the presentation can be accessed via Bio-Techne's Investor Relations website at https://investors.bio-techne.com/ or through the following link http://wsw.com/webcast/jeff126/tech/.
May 26, 2020 03:00 am ET
Leica Biosystems and Bio-Techne Announce European Launch of the CE-IVD RNAscope In Situ Hybridization Detection Kit
MINNEAPOLIS, May 26, 2020 /PRNewswire/ -- Bio-Techne (NASDAQ:TECH), a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities and Leica Biosystems, a global leader in workflow solutions and automation, are proud to announce the European launch of the CE-IVD marked RNAscope™ In Situ Hybridization Detection Kit for automation on the BOND-III platform. The combination of Bio-Techne's RNAscope and Leica's BOND-III will provide pathologists access to an unprecedented number of leading applications to support their diagnos
May 19, 2020 04:05 pm ET
Bio-Techne And Kantaro Biosciences Announce Partnership To Develop And Scale Production Of COVID-19 Serology Test
MINNEAPOLIS and NEW YORK, May 19, 2020 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) and the Mount Sinai Health System in New York, through its commercial affiliate Kantaro Biosciences LLC (Kantaro), today announced a partnership to initiate scaled manufacturing and distribution of testing kits based on the Mount Sinai-developed COVID-19 serology test. Kantaro Biosciences is a joint venture between Mount Sinai Health System ("Mount Sinai") and Renalytix AI (LSE: RENX) formed exclusively to ensure that diagnostic tests for critical health challenges are accessible to all. The Mount Sin
May 11, 2020 07:00 am ET
Bio-Techne Announces Release of GMP Cloudz™ Human T Cell Activation Kit
MINNEAPOLIS, May 11, 2020 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today announced the release of the GMP Cloudz™ Human T Cell Activation Kit. This is the first GMP-grade kit within the Cloudz product line addressing the need for robust, yet safe products within the clinical- and commercial-scale of the Cell and Gene Therapy manufacturing process. The kit contains Cloudz particles, which are dissolvable microspheres conjugated to GMP Grade, in-house manufactured CD3 and CD28 antibodies for the expansion of T cells. The GMP Cloudz Human T Cell Activation Kit seamlessly fits within
May 07, 2020 10:35 am ET
Bio-Techne Announces Publication of ExoDx™ Prostate (IntelliScore) EPI Test Clinical Utility Study
MINNEAPOLIS, May 7, 2020 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today announced a major publication in the Journal of Prostate Cancer and Prostatic Diseases entitled, Clinical Utility of the exosome based ExoDx™ Prostate (IntelliScore) EPI test in men presenting for initial Biopsy with a PSA 2-10ng/mL (link available here). Principal investigators Dr. Ronald Tutrone, Medical Director of Chesapeake Urology, and Dr. James McKiernan, Professor of Urology at Columbia University, demonstrated the ExoDx Prostate test, or EPI, delivered improved patient outcomes over standard of care
May 05, 2020 09:31 am ET
Thinking about trading stocks or options in Shopify, Walt Disney, JPMorgan Chase, Boeing, or Bio-Techne Corp?
NEW YORK, May 5, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for SHOP, DIS, JPM, BA, and TECH.
May 05, 2020 07:00 am ET
Bio-Techne To Present At The BofA Securities 2020 Health Care Conference
MINNEAPOLIS, May 5, 2020/ /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today announced that Chuck Kummeth, President and Chief Executive Officer, will present at the virtual BofA Securities 2020 Health Care Conference on Wednesday, May 13, 2020 at 9:40 a.m. EDT. A live webcast of the presentation can be accessed via Bio-Techne's Investor Relations website at https://investors.bio-techne.com/ or through the following link http://www.veracast.com/webcasts/bofa/healthcare2020/id62109638.cfm.
Apr 30, 2020 06:30 am ET
Bio-Techne Declares Dividend
MINNEAPOLIS, April 30, 2020 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) announced that its Board of Directors has decided to pay a dividend of $0.32 per share for the quarter ended March 31, 2020. The quarterly dividend will be payable May 22, 2020 to all common shareholders of record on May 11, 2020. Future cash dividends will be considered by the Board of Directors on a quarterly basis.
Apr 30, 2020 06:30 am ET
Bio-Techne Releases Third Quarter Fiscal 2020 Results
MINNEAPOLIS, April 30, 2020 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today reported its financial results for the third quarter ended March 31, 2020.
Apr 15, 2020 07:00 am ET
Bio-Techne's Exosome Diagnostics Launches ExoDx Prostate At-Home Collection Kit
MINNEAPOLIS, April 15, 2020 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH)  announced today that Exosome Diagnostics, a Bio-Techne brand, is launching an ExoDx™ Prostate Test At-Home Collection Kit for patients who are concerned about their prostate health. Millions of men recently had appointments cancelled for important procedures, like biopsy, to detect the presence of prostate cancer due to Shelter in Place orders issued to reduce the spread of Covid-19.  The at-home collection kit provides an immediate and cost-effective solution that enables a telemedicine/telehealth opportunity

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.